Skip to content

Zevra Therapeutics, Inc. ZVRA Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$37.33M-4.3%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$515K+214%
Arrowhead Research logo
Arrowhead ResearchARWR
$107.88M-5.6%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.68M-13.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$18.66M+84.3%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$13.53M+56.4%

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$773.23M+56.4%
Enterprise value$678.78M+30.8%
P/E6.2×
P/S6.3×-5.9×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s operating lease liabilities (total)?
Zevra Therapeutics, Inc. (ZVRA) reported operating lease liabilities (total) of $1.15M in Q1 2026.
How has Zevra Therapeutics, Inc.'s operating lease liabilities (total) changed year-over-year?
Zevra Therapeutics, Inc.'s operating lease liabilities (total) decreased by 34.3% year-over-year, from $1.75M to $1.15M.
What is the long-term trend for Zevra Therapeutics, Inc.'s operating lease liabilities (total)?
Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s operating lease liabilities (total) has grown at a -7.8% compound annual growth rate (CAGR), from $1.91M to $1.28M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.